UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A single amino acid substitution in the group 1 Trypanosoma brucei gambiense haptoglobin-hemoglobin receptor abolishes TLF-1 binding

PLoS pathogens, 2013-04, Vol.9 (4), p.e1003317

2013

Volltextzugriff (PDF)

Pyronaridine exerts potent cytotoxicity on human breast and hematological cancer cells through induction of apoptosis

PloS one, 2018-11, Vol.13 (11), p.e0206467

2018

Volltextzugriff (PDF)

Final 192‐week efficacy and safety of once‐daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV‐1‐infected treatment‐naïve patients in the ARTEMIS trial

HIV medicine, 2013-01, Vol.14 (1), p.49-59

2013

Volltextzugriff (PDF)

Cytokine Pathways in Cardiac Dysfunction following Burn Injury and Changes in Genome Expression

Journal of personalized medicine, 2022-11, Vol.12 (11), p.1876

2022

Volltextzugriff (PDF)

Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96‐week results from two randomized clinical trials

HIV medicine, 2018-11, Vol.19 (10), p.724-733

2018

Volltextzugriff (PDF)

SWIFT: Prospective 48-Week Study to Evaluate Efficacy and Safety of Switching to Emtricitabine/Tenofovir From Lamivudine/Abacavir in Virologically Suppressed HIV-1 Infected Patients on a Boosted Protease Inhibitor Containing Antiretroviral Regimen

Clinical infectious diseases, 2013-06, Vol.56 (11), p.1637-1645

2013

Volltextzugriff (PDF)

Novel Oridonin Analog CYD0682 Inhibits Hepatic Stellate Cell Activation via the Heat Shock Protein 90–Dependent STAT3 Pathway

The Journal of surgical research, 2024-06, Vol.298, p.14-23

2024

Volltextzugriff (PDF)

Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials

AIDS research and human retroviruses, 2020-01, Vol.36 (1), p.48-57

2020

Volltextzugriff (PDF)

Field Comparison of Carbon Dioxide Source with Biogents Sentinel-2 and Pro Traps for Adult Aedes Mosquito Surveillance

Journal of the American Mosquito Control Association, 2024-03, Vol.40 (1), p.75-77

2024

Volltextzugriff (PDF)

PARP1 Inhibition and Effect on Burn Injury-Induced Inflammatory Response and Cardiac Function

Journal of the American College of Surgeons, 2023-04, Vol.236 (4), p.783-802

2023

Volltextzugriff (PDF)

A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment-naïve patients

International journal of clinical practice (Esher), 2011-12, Vol.65 (12), p.1240-1249

2011

Volltextzugriff (PDF)

The ASSURE study: HIV‐1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir

HIV medicine, 2016-02, Vol.17 (2), p.106-117

2016

Volltextzugriff (PDF)

1372 ONCE DAILY PSI-7977 PLUS PEG-IFN/RBV IN HCV GT1: 98% RAPID VIROLOGIC RESPONSE, COMPLETE EARLY VIROLOGIC RESPONSE: THE PROTON STUDY

Journal of hepatology, 2011-03, Vol.54, p.S544-S544

2011

Volltextzugriff (PDF)

LP04 : A phase 3, open-label, single-arm study to evaluate the efficacy and safety of 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naïve or -experienced patients with chronic HCV genotype 1 infection and cirrhosis: Optimist-2

Journal of hepatology, 2015-04, Vol.62, p.S264-S265

2015

Volltextzugriff (PDF)

A new pyridazinone exhibits potent cytotoxicity on human cancer cells via apoptosis and poly-ubiquitinated protein accumulation

Cell biology and toxicology, 2019-12, Vol.35 (6), p.503-519

2019

Volltextzugriff (PDF)

Randomized comparison of metabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in treatment‐naïve HIV‐1‐infected patients

HIV medicine, 2011-11, Vol.12 (10), p.620-631

2011

Volltextzugriff (PDF)

O63 EFFICACY AND SAFETY OF THE ALL-ORAL REGIMEN, MK-5172/MK-8742 +/− RBV FOR 12 WEEKS IN GT1 HCV/HIV CO-INFECTED PATIENTS: THE C-WORTHY STUDY

Journal of hepatology, 2014-04, Vol.60 (1), p.S26-S26

2014

Volltextzugriff (PDF)

O165 SIMEPREVIR PLUS SOFOSBUVIR WITH/WITHOUT RIBAVIRIN IN HCV GENOTYPE 1 PRIOR NULL-RESPONDER/TREATMENT-NAIVE PATIENTS (COSMOS STUDY): PRIMARY ENDPOINT (SVR12) RESULTS IN PATIENTS WITH METAVIR F3–4 (COHORT 2)

Journal of hepatology, 2014-04, Vol.60 (1), p.S524-S524

2014

Volltextzugriff (PDF)

Vesatolimod (GS-9620) is safe and pharmacodynamically active in HIV-infected individuals

Journal of Virus Eradication, 2019-07, Vol.5, p.3-3

2019

Volltextzugriff (PDF)

A Rare Case of Erosive Esophagitis Due to Sarcina Ventriculi Infection

Curēus (Palo Alto, CA), 2023-01

2023

Volltextzugriff (PDF)

Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV

The New England journal of medicine, 2006-01, Vol.354 (3), p.251-260

2006

Volltextzugriff (PDF)

1206 ABT-072 OR ABT-333 COMBINED WITH PEGYLATED INTERFERON/RIBAVIRIN AFTER 3-DAY MONOTHERAPY IN HCV GENOTYPE 1 (GT1)-INFECTED TREATMENT-NAIVE SUBJECTS: 12-WEEK SUSTAINED VIROLOGIC RESPONSE (SVR12) AND SAFETY RESULTS

Journal of hepatology, 2012-04, Vol.56, p.S478-S478

2012

Volltextzugriff (PDF)

1187 ABT-450/RITONAVIR (ABT-450/R) COMBINED WITH PEGYLATED INTERFERON ALPHA-2A/RIBAVIRIN AFTER 3-DAY MONOTHERAPY IN GENOTYPE 1 (GT1) HCV-INFECTED TREATMENT-NAIVE SUBJECTS: 12-WEEK SUSTAINED VIROLOGIC RESPONSE (SVR12 ) AND SAFETY RESULTS

Journal of hepatology, 2012-04, Vol.56, p.S470-S470

2012

Volltextzugriff (PDF)

Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection

The New England journal of medicine, 2020-03, Vol.382 (13), p.1232-1243

2020

Volltextzugriff (PDF)

1 – 25 von 707

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(608)
Mit Volltextzugriff
(555)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(427)
Life Sciences & Biomedicine
(335)
Humans
(251)
Female
(188)
Male
(182)
Biological And Medical Sciences
(147)
Adult
(140)
Middle Aged
(123)
Medical Sciences
(111)
Infectious Diseases
(102)
Hiv Infections - Drug Therapy
(93)
Aged
(89)
Animals
(83)
Physical Sciences
(77)
Immunology
(65)
Fundamental And Applied Biological Sciences. Psychology
(64)
Human Immunodeficiency Virus
(64)
Chemistry
(62)
Hiv
(58)
Neurosciences & Neurology
(58)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

A single amino acid substitution in the group 1 Trypanosoma brucei gambiense haptoglobin-hemoglobin receptor abolishes TLF-1 binding

Pyronaridine exerts potent cytotoxicity on human breast and hematological cancer cells through induction of apoptosis

Final 192‐week efficacy and safety of once‐daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV‐1‐infected treatment‐naïve patients in the ARTEMIS trial

Cytokine Pathways in Cardiac Dysfunction following Burn Injury and Changes in Genome Expression

Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96‐week results from two randomized clinical trials

SWIFT: Prospective 48-Week Study to Evaluate Efficacy and Safety of Switching to Emtricitabine/Tenofovir From Lamivudine/Abacavir in Virologically Suppressed HIV-1 Infected Patients on a Boosted Protease Inhibitor Containing Antiretroviral Regimen

Novel Oridonin Analog CYD0682 Inhibits Hepatic Stellate Cell Activation via the Heat Shock Protein 90–Dependent STAT3 Pathway

Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials

Field Comparison of Carbon Dioxide Source with Biogents Sentinel-2 and Pro Traps for Adult Aedes Mosquito Surveillance

PARP1 Inhibition and Effect on Burn Injury-Induced Inflammatory Response and Cardiac Function

A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment-naïve patients

The ASSURE study: HIV‐1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir

1372 ONCE DAILY PSI-7977 PLUS PEG-IFN/RBV IN HCV GT1: 98% RAPID VIROLOGIC RESPONSE, COMPLETE EARLY VIROLOGIC RESPONSE: THE PROTON STUDY

LP04 : A phase 3, open-label, single-arm study to evaluate the efficacy and safety of 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naïve or -experienced patients with chronic HCV genotype 1 infection and cirrhosis: Optimist-2

A new pyridazinone exhibits potent cytotoxicity on human cancer cells via apoptosis and poly-ubiquitinated protein accumulation

Randomized comparison of metabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in treatment‐naïve HIV‐1‐infected patients

O63 EFFICACY AND SAFETY OF THE ALL-ORAL REGIMEN, MK-5172/MK-8742 +/− RBV FOR 12 WEEKS IN GT1 HCV/HIV CO-INFECTED PATIENTS: THE C-WORTHY STUDY

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

O165 SIMEPREVIR PLUS SOFOSBUVIR WITH/WITHOUT RIBAVIRIN IN HCV GENOTYPE 1 PRIOR NULL-RESPONDER/TREATMENT-NAIVE PATIENTS (COSMOS STUDY): PRIMARY ENDPOINT (SVR12) RESULTS IN PATIENTS WITH METAVIR F3–4 (COHORT 2)

Vesatolimod (GS-9620) is safe and pharmacodynamically active in HIV-infected individuals

A Rare Case of Erosive Esophagitis Due to Sarcina Ventriculi Infection

Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV

1206 ABT-072 OR ABT-333 COMBINED WITH PEGYLATED INTERFERON/RIBAVIRIN AFTER 3-DAY MONOTHERAPY IN HCV GENOTYPE 1 (GT1)-INFECTED TREATMENT-NAIVE SUBJECTS: 12-WEEK SUSTAINED VIROLOGIC RESPONSE (SVR12) AND SAFETY RESULTS

1187 ABT-450/RITONAVIR (ABT-450/R) COMBINED WITH PEGYLATED INTERFERON ALPHA-2A/RIBAVIRIN AFTER 3-DAY MONOTHERAPY IN GENOTYPE 1 (GT1) HCV-INFECTED TREATMENT-NAIVE SUBJECTS: 12-WEEK SUSTAINED VIROLOGIC RESPONSE (SVR12 ) AND SAFETY RESULTS

Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection

Suchergebnisse filtern